AFT Pharmaceuticals (ASX:AFP) Cash Flow from Investing: A$-8.3 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:AFP AFT Pharmaceuticals Ltd ASX:AFP
88 GF Score
Price A$3.94
GF Value A$3.43
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is AFT Pharmaceuticals Cash Flow from Investing?

AFT Pharmaceuticals ASX:AFP 88 Cash Flow from Investing is A$-8.3 Mil as of Mar. 2026. GuruFocus rates ASX:AFP with a GF Score™ of 88/100 and a GF Value™ of A$3.43 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the six months ended in Mar. 2026, AFT Pharmaceuticals spent A$0.0 Mil on purchasing property, plant, equipment. It gained A$0.0 Mil from selling property, plant, and equipment. It spent A$0.0 Mil on purchasing business. It gained A$0.0 Mil from selling business. It spent A$0.0 Mil on purchasing investments. It gained A$0.0 Mil from selling investments. It paid A$5.2Mil for net Intangibles purchase and sale. And it paid A$0.0 Mil for other investing activities. In all, AFT Pharmaceuticals spent A$5.2 Mil on investment activities in financial market and operating subsidiaries for the six months ended in Mar. 2026.


AFT Pharmaceuticals  (ASX:AFP) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

AFT Pharmaceuticals's purchase of property, plant, equipment for the six months ended in Mar. 2026 was A$-0.0 Mil. It means AFT Pharmaceuticals spent A$0.0 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

AFT Pharmaceuticals's sale of property, plant, equipment for the six months ended in Mar. 2026 was A$0.0 Mil. It means AFT Pharmaceuticals gained A$0.0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

AFT Pharmaceuticals's purchase of business for the six months ended in Mar. 2026 was A$0.0 Mil. It means AFT Pharmaceuticals spent A$0.0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

AFT Pharmaceuticals's sale of business for the six months ended in Mar. 2026 was A$0.0 Mil. It means AFT Pharmaceuticals gained A$0.0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

AFT Pharmaceuticals's purchase of investment for the six months ended in Mar. 2026 was A$0.0 Mil. It means AFT Pharmaceuticals spent {stock_data.stock.currency_symbol}}0.0 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

AFT Pharmaceuticals's sale of investment for the six months ended in Mar. 2026 was A$0.0 Mil. It means AFT Pharmaceuticals gained A$0.0 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

AFT Pharmaceuticals's net Intangibles purchase and sale for the six months ended in Mar. 2026 was A$-5.2 Mil. It means AFT Pharmaceuticals paid A$5.2 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

AFT Pharmaceuticals's cash from discontinued investing activities for the six months ended in Mar. 2026 was 0.0 Mil. It means AFT Pharmaceuticals paid A$0.0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

AFT Pharmaceuticals's cash from other investing activities for the six months ended in Mar. 2026 was A$0.0 Mil. It means AFT Pharmaceuticals paid A$0.0 Mil for other investing activities.


AFT Pharmaceuticals Cash Flow from Investing Related Terms


AFT Pharmaceuticals Cash Flow from Investing Historical Data

* Premium members only.

The historical data trend for AFT Pharmaceuticals's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AFT Pharmaceuticals Cash Flow from Investing Chart

AFT Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.20 -8.53 -8.84 -6.32 -8.13

AFT Pharmaceuticals Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.34 -3.62 -2.74 -3.12 -5.22
ASX:AFP
88GF Score
AFT Pharmaceuticals Ltd ASX:AFP
Cash Flow from Investing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AFT Pharmaceuticals Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

AFT Pharmaceuticals's Cash Flow from Investing for the fiscal year that ended in Mar. 2026 is calculated as:

AFT Pharmaceuticals's Cash Flow from Investing for the quarter that ended in Mar. 2026 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-8.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow from Investing of A$-8.3 Mil mean?
AFT Pharmaceuticals (ASX:AFP) has a Cash Flow from Investing of A$-8.3 Mil as of Mar. 2026. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for AFT Pharmaceuticals and its competitors.
Is AFT Pharmaceuticals' Cash Flow from Investing too high?
AFT Pharmaceuticals' current Cash Flow from Investing is A$-8.3 Mil. Overall, AFT Pharmaceuticals has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' Cash Flow from Investing compare to ZTS and UTHR?
AFT Pharmaceuticals' Cash Flow from Investing of A$-8.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Investing for a Drug Manufacturers company?
A good Cash Flow from Investing depends on the Drug Manufacturers industry context. However, Cash Flow from Investing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Investing mean?
A high Cash Flow from Investing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Investing is the amount of cash earned or paid from investing operations. View historical data for AFT Pharmaceuticals and its competitors. AFT Pharmaceuticals's current Cash Flow from Investing is A$-8.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (ASX:AFP) is currently considered Modestly Overvalued. The stock's GF Value™ is A$3.43, compared to a current price of A$3.94 — trading 14.9% above its estimated fair value. The current Cash Flow from Investing is A$-8.3 Mil. AFT Pharmaceuticals' overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Investing calculated?
Cash Flow from Investing is calculated from a company's financial statements. For AFT Pharmaceuticals (ASX:AFP), the current Cash Flow from Investing is A$-8.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AFT Pharmaceuticals (ASX:AFP) Overvalued in 2026?

Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be overvalued. The current stock price of A$3.94 is trading 14.9% above its estimated GF Value™ of A$3.43. GuruFocus considers AFT Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for ASX:AFP:

  • Cash Flow from Investing: A$-8.3 Mil
  • GF Value™: A$3.43 vs. price of A$3.94 (14.9% above fair value)
  • GF Score™: 88/100 with 5 warning signs

No single metric tells the full story. See the ASX:AFP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AFT Pharmaceuticals Business Description

Other Exchanges AFT:New Zealand
Address 129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
88GF Score

Get the complete analysis for ASX:AFP

Cash Flow from Investing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$3.94
Price
A$3.43
GF Value